Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Passive strategies for retirement prioritize low costs and broad market exposure, delivering reliable long-term growth without constant tweaking.
23,939 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
When a leading floor-care company hits a rough patch, headlines follow. This look explains why Tennant stock plummeti...
Dycom Industries sits at the center of the U.S. buildout wave. This article breaks down the 2026 earnings outlook, ke...
G-III Apparel faced a sharp slide after its latest earnings, signaling investor caution about licensing-heavy fashion...
Oil price swings ripple through markets, but not all stocks feel the heat equally. This piece spotlights two resilien...
Rhode Island’s small firms drive growth, jobs, and innovation. This article explains how a high-earner surtax would a...
Oklo stock fell further as traders digested quarterly results and a new regulatory filing. This article breaks down w...
Fluor dropped 26% and headlines lit up. But a solid long-term thesis for this EPC powerhouse requires more than a fla...
A smaller biotech is stealing headlines in 2026 by delivering strong trial results and strategic collaborations. This...
AI-driven demand pushed Intel, AMD, Arm and other AI stocks higher today. Learn what drove the rally, what it means f...
When SpaceX first hit the public markets, traders expected spectacle but not necessarily sustainability. A surprising...
Axon Enterprise stock popped as investors weighed the company’s expanding product lineup, software growth, and a grow...